Figure 4.
A patient with iCCA received lenvatinib+sintilimab as 2nd-line systemic therapy. The CT images before (A) and after (B) nearly 1-year therapy showed a significant shrinkage of the target lesion, which was mainly located in the left hemi-liver and invaded the left branch of portal vein. (C) Shows the HE staining of the tumor and (D) displays the photomicrographs of immunohistochemistry staining of PD-L1 expression.